Skip to main content

Covid JN.1 sub-variant: Symptoms, precautions & other FAQs

The JN.1 variant of Covid, causing concern in India, has mild to moderate symptoms such as fever, runny nose, sore throat, headaches, loss of appetite, and extreme fatigue. Gastrointestinal problems may also occur. The central government has issued advisories to state governments, urging adequate health arrangements. The WHO classifies JN.1 as a "variant of interest" with limited threat. Vaccinations targeting the spike protein should remain effective against JN.1. To prevent infection, experts recommend masking up in crowded areas, staying in well-ventilated spaces, and frequent handwashing.

from Times of India https://ift.tt/k1lYbTO
via

Comments

Popular posts from this blog

Wet spell likely in north & central India till Jan 9: IMD

The India Meteorological Department (IMD) on Wednesday predicted a wet spell over northwest India, including Delhi-NCR, Punjab and Haryana, and central India till January 9 due to two consecutive active western disturbances. It, however, said that there may not be cold wave conditions over north India during the next five days. from Times of India https://ift.tt/34pJ29g via

Kashmiri Pandit killed in J&K's Shopian, 7th since 2020

A terrorist shot dead 43-year-old Kashmiri Pandit farmer Puran Krishan Bhat outside his home in Choudharygund village of south Kashmir’s Shopian district Saturday morning, triggering protests in Jammu against the latest targeted attack on the community. DIG Sujit Kumar said Kashmir Freedom Fighter (KFF), the proxy name of a terrorist outfit, claimed responsibility for the attack on Bhat. from Times of India https://ift.tt/Sk9sv5q via

Molnupiravir has serious safety concerns: ICMR chief

Antiviral drug molnupiravir, which recently got approval from the drug regulator and is being launched by several local drug makers, has serious safety concerns, and thus has not been included in the national Covid-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava said. from Times of India https://ift.tt/3pXmODT via